A Randomized Open-Labeled Trial of Methotrexate as a Steroid-Sparing Agent for Patients With Generalized Myasthenia Gravis

A Randomized Open-Labeled Trial of Methotrexate as a Steroid-Sparing Agent for Patients With Generalized Myasthenia Gravis

Background and PurposeTwo clinical trials assessing the steroid-sparing effect of methotrexate (MTX) yielded conflicting results. Our objective was to investigate whether MTX would show a steroid-sparing effect in the treatment of generalized myasthenia gravis (MG) patients who fitted Myasthenia Gra...

Full description

Bibliographic Details
Main Authors: Li Di, Faxiu Shen, Xinmei Wen, Yan Lu, Wenjia Zhu, Min Wang, Yuwei Da
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-03-01
Series:Frontiers in Immunology
Subjects:
generalized myasthenia gravis
methotrexate
steroid-sparing effect
randomized
clinical trial
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.839075/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.839075/full

Similar Items